Il Nuovo Postiglione - OpenAI chief says it needs new open-source strategy

NYSE - LSE

RBGPF	-4.07%	76	$
BCC	-0.1%	73.02	$
JRI	0.07%	14.08	$
CMSC	0.14%	24.315	$
NGG	0.29%	77.17	$
SCS	-0.9%	16.63	$
BCE	-1.41%	23.48	$
CMSD	0%	24.65	$
GSK	1.28%	43.8	$
RIO	0.55%	70.93	$
RELX	0.15%	46.64	$
RYCEF	1.2%	14.95	$
AZN	0.92%	84.06	$
BTI	0.04%	52.09	$
VOD	1.43%	11.9	$
BP	0.66%	34.77	$

OpenAI chief says it needs new open-source strategy

TECHNOLOGY 01.02.2025

OpenAI chief says it needs new open-source strategy / Photo: Andrew Harnik - GETTY IMAGES NORTH AMERICA/AFP

OpenAI chief Sam Altman on Friday said his high-profile artificial intelligence company is "on the wrong side of history" when it comes to being open about how its technology works.

Text size:

Altman's comments came during an Ask Me Anything session on Reddit where he fielded questions including whether he would consider publishing OpenAI research.

Altman replied he was in favor of the idea and that it is a topic of discussion inside San Francisco-based OpenAI.

"I personally think we have been on the wrong side of history here and need to figure out a different open source strategy," Altman said.

"Not everyone at OpenAI shares this view, and it's also not our current highest priority."

Chinese AI newcomer DeepSeek has made headlines for its R1 chatbot's supposed low cost and high performance, but also its claim to be a public-spirited "open-source" project in contrast to closed alternatives from OpenAI and Google.

Open source refers to the practice of programmers revealing the source code of their software, rather than just the "compiled" program ready to run on a computer.

This has clashed with private companies' pursuit of revenue and intellectual property protection.

Meta, DeepSeek and France-based AI developer Mistral claim to set themselves apart by allowing developers free access to their tools' inner workings.

A member of the Reddit group asked Altman whether DeepSeek has changed his plans for future OpenAI models.

"It's a very good model," Altman said of DeepSeek.

"We will produce better models, but we will maintain less of a lead than we did in previous years."

F.M.Buffo--INP

Featured

Cambridge Isotope Laboratories, Inc. Unveils ISOAPI-D - a New Standard in Deuterated Reagents for Pharmaceutical Innovation - at CPhI Frankfurt 2025

With ISOAPI-D, CIL offers pharmaceutical partners a secure, global supply of deuterated reagents - manufactured to the highest quality standards for faster, more efficient API development.

Cambridge Isotope Laboratories, Inc. and Chemtatva Chiral Solutions Pvt. Ltd. to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad, India

Strategic Partnership to Establish Cambridge Isotope Laboratories, Pvt. Ltd. in Hyderabad's Genome Valley, Enhancing Global Production and Supply of Isotopically Enriched Chemical Solutions for Pharmaceutical and Electronics Industries

Novartis acquiring US firm Avidity Biosciences for $12 bn

Swiss pharmaceutical giant Novartis announced Sunday it had agreed to buy Avidity Biosciences, with the San Diego-based biopharmaceutical company being valued at $12 billion.

'Food for the soul': Germany's Yiddish revival

A push to revitalise Yiddish and its cultural traditions has gained momentum in Germany, the very place where the Nazi regime's Holocaust sought to eradicate the Jewish communities who spoke it.